Available Grant Opportunities

 

Week of June 11-15th, 2018

Check back often for weekly updates

 

INTERNAL GRANT OPPORTUNITIES

Internal Funding Opportunities & Limited Submission Grants:

 

A. Alfred Taubman Medical Research Institute – Innovation Programs: Phenotyping in the Clinical Setting (Award amount variable, rolling deadline).  

http://www.taubmaninstitute.org/science/taubman-institute-innovation-program/ 

The Taubman Institute is seeking to support new or existing teams of scientists to develop novel and impactful approaches to integrate their research programs into the clinic setting. The goal is to perform systematic, multiscale phenotyping to gain insights into individual variation in the susceptibility, progression, course, or outcomes of disease. The institute will partner with investigators to support the development and implementation of their research programs. This will include, but not be limited to, development of a research plan, identification of research partners within and external to U-M, infrastructure and database development, support for clinician and ancillary personnel in the clinic, clinical data collection, biological specimen collection, remote data collection, initiation of research plan, and data analysis. Our goal is to make every patient a research subject, and to define the genetic, environmental, behavioral and other components of individuals that contribute to their distinct emergent property related to health and disease. The goal is to also utilize the data to stratified an individual in order apply interventions that lead to the prevention, improved treatment, or cure of disease. The institute anticipates investing up to $2.5 million per year to support the funded projects. What are the criteria for funding? Impact on improving the lives of patients; Innovation in understanding the variability in onset or progression of disease, and reasons for differential response to treatment; Potential for future funding by the NIH or other external agencies; Potential for increased reimbursement for care by insurance companies, or cost savings to the medical system; and, Enhanced interactions with basic or other science disciplines (teams). Letter of intent:  Description of the proposed program. Who is going to work together and what will be their roles? Have you worked together in the past? Where do you want to perform this work? What infrastructure is needed to accomplish the goals? Who will you need to partner with to succeed? What are the present barriers to your success? What are your plans for downstream funding? Note: not all of these points must be addressed in the LOI. We seek to understand your vision for bringing science into the clinic. The main request here is for an outline of what you want to do and why it will be impactful. There is no deadline. Letters of intent are accepted on a rolling basis, and should be submitted to managing director Grace Wu (glwu@umich.edu). We encourage questions. You may contact us with written questions through Grace Wu (glwu@umich.edu). We’re happy to meet with individuals or teams to discuss ideas.

 

Michigan Center for Therapeutic Innovation and Fast Forward Medical Innovation 2018 Request for Proposal for the U-M Therapeutic Innovation Fund ($150,000 award, deadline July 13th, 2018).  https://umms.infoready4.com/#competitionDetail/1772724  The Michigan Center for Therapeutic Innovation and Fast Forward Medical Innovation (FFMI) are happy to announce the 2018 RFP for the U-M Therapeutic Innovation Fund. The U-M Therapeutic Innovation Fund RFP: The Michigan Center for Therapeutic Innovation (MCTI) and Fast Forward Medical Innovation (FFMI) offer a five-year, $2.5 million fund created to accelerate the discovery and translation of therapeutic candidates at the University of Michigan. The fund supports the discovery and optimization of small molecule lead compounds for projects with a specific, novel, and testable drug discovery hypothesis. Selected projects receive funding and resources to support medicinal chemistry efforts through MCTI and funding for drug design, assay development, cell biology, structural biology, and pharmacology (up to $150,000 in value for each award for up to 18 months). A pre-submission application and meeting must be completed on or before Friday, July 13, 2018. The submission deadline for the full proposal will be on Friday, July 27, 2018 at 5pm. Please contact Jason Rech at jcrech@umich.edu or Visha Krishnan at kvisha@umich.edu if you have any questions about the funding opportunity or would like to schedule a pre-submission meeting.

 

2019 Searle Scholars Program ($300,000 award, internal competition deadline July 23rd, 2018).  https://umms.infoready4.com/?mc_cid=90620d8481&mc_eid=658fd7e061#competitionDetail/1772720

Nominations of faculty from all units of the University are welcome. Program Focus: The Searle Scholars Program gives grants to support independent research in medicine, chemistry, and the biological sciences for exceptional early-career scientists who have recently begun their appointment at the assistant professor level, and whose appointment is their first tenure-track position. More information on the Searle Scholars Program website:  http://www.searlescholars.net/  The University may submit two candidates to apply for the 2019 Searle Scholars Program. The Searle Scholars Program online application submission system will be available to selected individuals once nominations have been placed. The final application submission deadline is Friday, September 28, 2018 (5:00 PM CDT). Funding Available: $300,000 ($100,000 per year for a three year period). Questions: Please contact Paula Van Velden (734) 615-8802, paulavan@umich.edu or Laura Hessler (734) 615-6575, lauralh@umich.edu. Searle Scholars Program Information Session: Thursday, June 28, 2018, 2:00 PM - 3:00 PM, Taubman Library room #5000.  Maureen Martin, Executive Director for Foundation Relations and Joseph Piffaretti, Senior Director for Corporate and Foundation Relations will conduct an information session on the Searle Scholars Program covering: Overview of the Searle Scholar Program; The Application Process; Writing the Proposals; Common Strengths and Weaknesses; and, Q&A.  Please RSVP for the Information Session. 2019 Searle Scholars Program Internal Deadline: Monday, July 23, 2018 (11:59 PM EDT).

 

EXTERNAL GRANT OPPORTUNITIES

 

American Foundation for Suicide Prevention –

  • 2018 Focus Grants ($1.5 million, Letter of Intent deadline August 1st, 2018).  https://afsp.org/our-work/research/grant-information/the-focus-grants/  Each year our research department requests applications for innovative, high-risk, potentially high-yield projects that focus on a specific area of suicide prevention. Short-Term Risk: The Focus Grant for Short-Term Risk is open to innovative, potentially high-yield proposals that focus on short-term risk for suicide. Goal: To develop identification and/or intervention strategies for short-term suicide risk that can be implemented in clinical settings. Funding: Up to $500,000 per year for up to three years. Reaching 20% by 2025: AFSP has set a goal to reduce our nation’s suicide rate 20% by 2025. We believe that by targeting areas known to contribute to suicide burden we can reach this goal. This Focus Grant RFA seeks applications that address potential biological, psychological, social and/or environmental pathways and interventions that can significantly reduce the national suicide rate if ultimately implemented on a large scale. Goal: Universal, selective and indicated interventions that target one or more specific risk factors for suicide and that, if implemented on a large scale, would reduce the annual U.S. suicide rates. Funding: Up to $500,000 per year for up to three years. Blue Sky Research Grant: Supports an innovative, impactful study in an area of suicide research that will achieve significant goals. This mechanism is intended for studies that, by their very nature, are clearly beyond the financial scope of our Innovation Grants. Goal: Innovative projects in new areas of investigation with potentially high impact for the understanding and prevention of suicide. Open to all fields of inquiry.

 

  • Linked Standard Research Innovation Grants ($300,000 award, Letter of Intent deadline September 15th, 2018).  https://afsp.org/our-work/research/grant-information/ Grants awarded to investigators at any level performing research involving two or more unique sites with each site contributing unique expertise, as well as data collection. Up to $300,000 over 2 years. Applicants must submit a Letter of Intent by September 15 to be eligible to apply.

 

  • Distinguished Investigator Innovation Grants ($125,000 award, deadline November 15th, 2018).  https://afsp.org/our-work/research/grant-information/ Grants awarded to investigators at the level of associate professor or higher with an established record of research and publication on suicide. Up to $125,000 over 2 years. Due Date: November 15, 2018.

 

  • Postdoctoral Research Fellowship Innovation Grants ($112,000 award, deadline November 15th, 2018).  https://afsp.org/our-work/research/grant-information/  Grants awarded to investigators who have received a Ph.D., M.D., or other doctoral degree within the preceding six years and have had no more than three years of fellowship support. Up to $112,000 over 2 years (Salary of $48,000 per year. Allowance of $8,000 per year.)  Due Date: Nov. 15, 2018.

 

 

  • Young Investigator Innovation Grants ($90,000 award, deadline November 15th, 2018).  https://afsp.org/our-work/research/grant-information/Grants awarded to investigators at or below the level of assistant professor. These grants must allocate $10,000 ($5,000 per year) of their award for an established suicide researcher to mentor the Young Investigator. AFSP is available to assist you in identifying a suitable mentor. Up to $90,000 over 2 years Due Date: Nov. 15, 2018.

 

Crohn’s & Colitis Foundation –

  • Fibrosis Initiative – Biology of Fibrosis in IBD ($900,000 award, deadline September 7th, 2018). http://www.crohnscolitisfoundation.org/science-and-professionals/research/fibrosisrfp.html  Half of all Crohn's disease (CD) patients will develop disease complications, one which is development of fibrotic strictures (fibrostenosis), leading to GI tract obstruction and severe clinical consequences. Fibrostenosis is also a serious problem for ulcerative colitis (UC) with approximately 8% incidence over the lifetime. Currently there is no clinical solution for preventing or treating fibrostenosis in patients with inflammatory bowel disease (IBD), except for surgical intervention. Therefore, there is a great unmet need to understand fibrotic complications in IBD and how to prevent and treat them. Scope: The Crohn's & Colitis Foundation seeks to fund studies focused on investigating the biological mechanisms leading to, and protecting from, fibrosis in IBD. These studies should be built upon clinical observations and/or published evidence in human IBD. Particular interest will be on proposals that address one or more of the following areas: Pathophysiology of fibrosis based on documented patterns of gene expression; Cell biological mechanisms of fibrosis – role of different cell types; and, Biology of strictureplasty. Funding Terms: $900,000 for three years ($300,000/year, contingent on reaching annual milestones). Application Deadline: September 7, 2018.

 

  • Novel Technologies Initiative – Sensor Technologies to Monitor Inflammation in IBD ($125,000 award, deadline September 7th, 2018). http://www.crohnscolitisfoundation.org/science-and-professionals/research/sensorsrfp.html  Crohn’s & Colitis Foundation has recognized the necessity to advance research focused on novel technologies to address unmet clinical needs in IBD, particularly relating to continuous or periodic monitoring of inflammation in IBD. Scope: The purpose of this initiative is to support the development of sensor technologies that can be implemented to detect and monitor inflammation in the context of IBD. Proposed technology should meet the following criteria: Minimally invasive detection of active inflammation. Preferably, the signals detected should be related to biological processes regarded to be causative and/or highly correlated with intestinal inflammation in IBD (e.g. cytokine levels, presence of proinflammatory immune cells, proinflammatory mediators, etc.) and should be informative with respect to symptoms (e.g. active "flare-up" prior to observation of severe symptoms). Sampling of data should be continuous or periodic during daily life, specifically, technologies, such as sensors/ biosensors/ nano-sensors, implantable, ingestible, wearable or environmental devices, will be considered. Have the potential to reach clinical studies within the next 3-4 years. Funding Terms: $125,000 for one year (inclusive of 10% indirect cost) Application Deadline: September 7, 2018.

 

Simons Foundation Autism Research Initiative – Bridge to Independence Award ($495,00 award, Letter of Intent deadline August 6th, 2018). https://www.sfari.org/grant/bridge-to-independence-award-request-for-applications/?tab=rfa Grants awarded through the Bridge to Independence Award program are intended to invest in the next generation of top autism investigators by identifying talented early-career scientists interested in autism research and facilitating their transition to independent research careers. The BTI Award program welcomes applications that span the breadth of science that SFARI normally supports, including genetics, molecular mechanisms, circuits and systems, and clinical science. While we encourage applications from postdoctoral fellows who are working on autism-related projects, we would like to stress that this award is also open to researchers who are not currently working on autism but who are interested in starting research projects in this area and who have expertise that could be brought to bear on this complex disorder. This request for applications (RFA) is aimed at senior postdoctoral fellows who intend to seek tenure-track faculty positions during the 2018-2019 academic year. Successful applicants will receive a commitment of $495,000 over three years, activated upon assumption of a tenure-track professorship. Letters of recommendation and LOIs due August 6, 2018.

 

Patient-Centered Outcomes Research Institute (PCORI) –

  • Eugene Washington PCORI Engagement Award: Dissemination Initiative ($300,000 award, Letter of Intent deadline October 1st, 2018). https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative  Through this award, PCORI seeks to fund projects designed by organizations and communities with established relationships with end users to disseminate the findings from PCORI-funded studies-on their own or as part of the body of existing evidence relevant to the PCORI-funded research findings. Funding Mechanism: The Eugene Washington PCORI Engagement Awards are issued as firm‐fixed‐price “Service” or “Mission‐Based” Contracts. They are not research awards, nor should they be treated as such. Applicants are expected to discuss the announcement and the potential resulting contractual mechanism with their contracts and grants management office to ensure they are able to accept it. This Engagement Award will give organizations and communities the opportunity to propose meaningful dissemination projects aimed at spreading awareness and increasing knowledge of new evidence from PCORI-funded research, targeted directly to patients, clinicians, and others who can use this information to inform healthcare decisions. The Eugene Washington PCORI Engagement Award: Dissemination Initiative program, a research support—not research—funding opportunity, is now accepting applications (letters of inquiry) for projects up to two years in duration, and up to $300,000 in total costs. Letter of Intent (LOI) Deadline October 1, 2018 by 5:00 p.m. (ET).

 

  • Eugene Washington PCORI Engagement Award: Capacity Building ($250,000 award, Letter of Intent deadline October 1st, 2018).https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building The goal is to support projects that will build a community that is better able to participate in patient‐centered outcomes research (PCOR) and comparative clinical effectiveness research (CER), and to serve as channels to disseminate study results. Funding Mechanism: The Eugene Washington PCORI Engagement Awards are issued as firm‐fixed‐price “Service” or “Mission‐Based” Contracts. They are not research awards, nor should they be treated as such. Applicants are expected to discuss the announcement and the potential resulting contractual mechanism with their contracts and grants management office to ensure they are able to accept it. The Eugene Washington PCORI Engagement Award: Capacity Building program, a research support—not research—funding opportunity, is now accepting applications (letters of inquiry) for projects up to two years in duration, and up to $250,000 in total costs. These projects will build a community of individuals and organizations better able to participate in PCOR/CER, and/or develop infrastructure and partnerships to disseminate PCORI‐funded research results. Letter of Intent (LOI) Deadline: October 1, 2018 by 5 p.m. (ET).

 

Cystic Fibrosis Foundation –

  • Clinical Research Award ($150,000+ award, Letter of Intent deadline July 12th, 2018).  https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Research-Awards/Clinical-Research-Award/  The Cystic Fibrosis Foundation offers competitive awards to support clinical research projects directly related to cystic fibrosis treatment and care. The intent of the Clinical Research Award program is to provide support for investigator-initiated clinical research projects that have the potential to make an important contribution to the Cystic Fibrosis Foundation's mission. Research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of cystic fibrosis, using clinical, translational, or epidemiologic study approaches. Applicants must demonstrate access to a sufficient number of CF patients and to appropriate controls. Up to $150,000 per year (plus 8 percent indirect costs) for a maximum of three years may be requested for single-center clinical research awards. For multi-center clinical research, the potential award is up to $350,000 per year (plus 8 percent for indirect costs) for a maximum of three years. Areas of Encouragement:  Applications may address any topic area advancing CF care, treatment, or research; however, applications focusing on certain areas are particularly encouraged. These areas were selected by people with CF, family members, and caregivers, who were invited to participate in a survey to identify the clinical research topic areas the CF community feels are the most important to them. Over 1,900 responses were collected from the survey and used to create research “areas of encouragement." The top 10 areas prioritized by the CF community are listed below:  Respiratory microorganism detection and treatment; Gastrointestinal symptoms (including, but not limited to, GERD, DIOS, and pancreatitis); Reducing treatment burden; CF-related diabetes; Diet and nutrition; Mental health; CF-related liver disease; Exercise; Sinus disease; and, Allergies and asthma. Deadline: Letter of Intent: July 12, 2018.

 

  • Clinical Pilot and Feasibility Award ($100,000+ award, Letter of Intent deadline July 12th, 2018).  https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Research-Awards/Clinical-Pilot-and-Feasibility-Award/ The Clinical Pilot and Feasibility Award is intended to support a project involving human subjects or samples that will develop and test new hypotheses and/or new methods in research areas relevant to cystic fibrosis. The intent of the Clinical Pilot and Feasibility Award is to enable investigators to collect sufficient preliminary data to determine the best strategies and methods for approaching a major question that ultimately will require assessment through a larger scale research and/or multi-center, collaborative clinical trial. Support may be requested for $50,000 annually (plus 8 percent for indirect costs) for up to two years. Special consideration will be given to those projects that pursue new approaches, under-researched topics, or more creative avenues of research to address the problems of cystic fibrosis. Applications for continued funding of the same project, or for long-term support of an investigator, will not be considered. Areas of Encouragement: Applications may address any topic area advancing CF care, treatment, or research; however, applications focusing on certain areas are particularly encouraged. People with CF, family members, and caregivers were invited to participate in a survey to identify the clinical research topic areas the CF community feels are the most important to them. Over 1,900 responses were collected from the survey and used to create research “areas of encouragement." The top 10 areas prioritized by the CF community are listed below:  Respiratory microorganism detection and treatment; Gastrointestinal symptoms (including, but not limited to, GERD, DIOS, and pancreatitis); Reducing treatment burden; CF-related diabetes; Diet and nutrition; Mental health; CF-related liver disease; Exercise; Sinus disease; and, Allergies and asthma. Deadline: Letter of Intent: July 12, 2018.

 

Alzheimer’s Drug Discovery Foundation – Accelerating Drug Discovery for Frontotemporal Degeneration ($150,000 award, Letter of Intent deadline July 13th, 2018).  https://www.alzdiscovery.org/research-and-grants/funding-opportunities/accelerating-drug-discovery-for-ftd Research investigating the pathogenic mechanisms underlying frontotemporal degeneration (FTD) is advancing, creating new targets for drug discovery. However, there remains a global gap in FTD drug discovery research. The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs for FTD through this request for proposals (RFP). Funding Priorities: Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME.

 

Testing of novel lead compounds, biologics, or repurposed drug candidates in relevant animal models for in vivo pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies. For in vivo efficacy studies proposals should: Demonstrate blood-brain barrier penetration (if the intended target is in the CNS); Justify dosing administration and regimen with in vivo PK/PD data; and, Include measures of target engagement. For studies testing repurposed drugs, proposals should: Evaluate known side effects of the drug and how well they would be tolerated by the intended FTD patients; Identify a supplier that will provide sufficient quantities of the drug or compound to complete the study aims; and, Demonstrate plans to develop novel intellectual property around the repurposing/repositioning strategy. This RFP does NOT support target identification, target validation, assay development, or high-throughput and high-content screening. Average Award: $100,000-$150,000. Letter of Intent: July 13, 2018.

 

CDG CARE (Community Alliance & Resource Exchange) – Request for Letters of Intent ($100,000 award, Letter of Intent deadline July 27th, 2018).  http://cdgcare.com/ CDG CARE (Community Alliance and Resource Exchange) is a nonprofit 501(c)(3) organization founded by parents seeking information and support for the group of disorders known as Congenital Disorders of Glycosylation (CDG). CDG CARE is committed to raising awareness, providing resources, fostering collaboration, and advocating for scientific research to advance the diagnosis and treatment of CDG. We are currently soliciting Letters of Intent (LOIs) for new research grants that are designed to promote science that will lead to greater understanding, treatments and a cure for CDG.

Proposals that may be supported may include, but are not limited to: 1) Basic, translational, or clinical research projects that support investigative approaches to advancing therapeutic outcomes for CDG. 2) Funding intramural and extramural scientific projects that may benefit the CDG community. Maximum Single Grant Allowed: $50,000 per year.  Maximum Length of Grant: Two years.  Letters of Intent should be submitted via email to info@cdgcare.com by July 27, 2018.

 

Pablove Foundation – Opsoclonus Myoclonus Syndrome (OMS (Research Seed Grants ($100,000 award, deadline August 17th, 2018).https://proposalcentral.altum.com/GrantOpportunities.asp?GMID=139  The Pablove Foundation is interested in principal investigators who will join us in taking risks, pushing for new solutions, and harnessing the transformative power of science in their research. We are looking for hypothesis driven ideas that will further our understanding of OMS, it’s treatment, and outcomes. The Pablove Foundation Seed Grant provides direct funds of $100,000 over 2 years. Full Proposals Due: August 17, 2018- 5:00 PM EST/